Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Pleiotropic Effect of Dronedarone Beyond Antiarrhythmic Agent: Reduction of Hypertrophy

  • Jung-Joon Cha (Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine)
  • Received : 2024.02.14
  • Accepted : 2024.02.26
  • Published : 2024.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Kim D, Yang PS, Joung B. Optimal rhythm control strategy in patients with atrial fibrillation. Korean Circ J 2022;52:496-512. https://doi.org/10.4070/kcj.2022.0078
  2. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024;149:e1-156.
  3. Hohnloser SH, Crijns HJ, van Eickels M, et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78. https://doi.org/10.1056/NEJMoa0803778
  4. Rosa GM, Bianco D, Parodi A, et al. Pharmacokinetic and pharmacodynamic profile of dronedarone, a new antiarrhythmic agent for the treatment of atrial fibrillation. Expert Opin Drug Metab Toxicol 2014;10:1751-64. https://doi.org/10.1517/17425255.2014.974551
  5. Iram F, Ali S, Ahmad A, Khan SA, Husain A. A review on dronedarone: Pharmacological, pharmacodynamic and pharmacokinetic profile. J Acute Dis 2016;5:102-8. https://doi.org/10.1016/j.joad.2015.10.002
  6. Heusch G, Schulz R. Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and brain. Cardiovasc Drugs Ther 2012;26:257-63. https://doi.org/10.1007/s10557-012-6379-z
  7. Quintana-Villamandos B, Gomez de Diego JJ, Delgado-Martos MJ, et al. Dronedarone produces early regression of myocardial remodelling in structural heart disease. PLoS One 2017;12:e0188442.
  8. Chen C, Hu S, Hu HJ, et al. Dronedarone attenuates Ang II-induced myocardial hypertrophy through regulating SIRT1/FOXO3/PKIA axis. Korean Circ J 2024;54:172-86. https://doi.org/10.4070/kcj.2023.0197
  9. Sotomayor-Flores C, Rivera-Mejias P, Vasquez-Trincado C, et al. Angiotensin-(1-9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway. Cell Death Differ 2020;27:2586-604. https://doi.org/10.1038/s41418-020-0522-3
  10. Pazo-Sayos L, Gonzalez MC, Quintana-Villamandos B. Inhibition of the NFATc4/ERK/AKT pathway and improvement of thiol-specific oxidative stress by dronedarone possibly secondary to the reduction of blood pressure in an animal model of ventricular hypertrophy. Front Physiol 2020;11:967.